Home » Stocks » AEZS

AEterna Zentaris Inc. (AEZS)

Stock Price: $0.958 USD 0.009 (0.92%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $0.945 -0.013 (-1.36%) May 7, 7:49 PM
Market Cap 118.78M
Revenue (ttm) 3.65M
Net Income (ttm) -5.12M
Shares Out 121.15M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.958
Previous Close $0.949
Change ($) 0.009
Change (%) 0.92%
Day's Open 0.933
Day's Range 0.931 - 0.980
Day's Volume 1,340,137
52-Week Range 0.290 - 3.620

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...

2 days ago - GlobeNewsWire

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets

2 days ago - GlobeNewsWire

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology

4 days ago - GlobeNewsWire

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

1 week ago - GlobeNewsWire

As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other stocks mentioned: MICT, ZSAN
1 week ago - PennyStocks

– Company executing on growth strategy to build-out pipeline of development assets

1 month ago - GlobeNewsWire

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

1 month ago - GlobeNewsWire

Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting H...

1 month ago - InvestorPlace

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-1...

1 month ago - Benzinga

- Company secures next step to continue to build-out pipeline of assets

1 month ago - GlobeNewsWire

AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Wor...

1 month ago - InvestorPlace

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will ...

1 month ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics an...

2 months ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...

2 months ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...

2 months ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...

2 months ago - GlobeNewsWire

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the run are Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Te...

Other stocks mentioned: ALPP, ENZC, OCGN
2 months ago - OTC PR Wire

Aeterna Zentaris (AEZS) stock is soaring higher on Monday with heavy trading even with there being a lack of news about the company. The post AEZS Stock: 7 Things to Know About Aeterna Zentaris as the B...

2 months ago - InvestorPlace

- Company secures next step to continue to build-out pipeline of assets

3 months ago - GlobeNewsWire

- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis opti...

3 months ago - GlobeNewsWire

CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics an...

3 months ago - GlobeNewsWire

– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –

3 months ago - GlobeNewsWire

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics an...

4 months ago - GlobeNewsWire

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical com...

5 months ago - GlobeNewsWire

- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million   - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“S...

5 months ago - GlobeNewsWire

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021

6 months ago - GlobeNewsWire

– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth

7 months ago - GlobeNewsWire

- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT -

7 months ago - GlobeNewsWire

- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults -

7 months ago - GlobeNewsWire

 – Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency

9 months ago - GlobeNewsWire

CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc . (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutic...

9 months ago - GlobeNewsWire

CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeuti...

9 months ago - GlobeNewsWire

CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing ...

9 months ago - GlobeNewsWire

CHARLESTON, S.C., July 30, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut...

9 months ago - GlobeNewsWire

CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...

9 months ago - GlobeNewsWire

CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut...

10 months ago - GlobeNewsWire

CHARLESTON, S.C., July 01, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut...

10 months ago - GlobeNewsWire

CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc.  (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut...

10 months ago - GlobeNewsWire

CHARLESTON, S.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeuti...

10 months ago - GlobeNewsWire

CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeuti...

11 months ago - GlobeNewsWire

CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

11 months ago - GlobeNewsWire

CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...

1 year ago - GlobeNewsWire

– Modifications recommended for some key elements of planned safety and efficacy Study P02 –

1 year ago - GlobeNewsWire

– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

1 year ago - GlobeNewsWire

CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...

1 year ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developin...

1 year ago - GlobeNewsWire

CHARLESTON, S.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developin...

1 year ago - GlobeNewsWire

Presentation on Monday, February 17th at 11:30 a.m. ET Presentation on Monday, February 17th at 11:30 a.m. ET

1 year ago - GlobeNewsWire

– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic –

1 year ago - GlobeNewsWire

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maxi... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 1996
CEO
Klaus Paulini
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
AEZS
Full Company Profile

Financial Performance

In 2020, AEZS's revenue was $3.65 million, an increase of 586.47% compared to the previous year's $532,000. Losses were -$5.12 million, -15.29% less than in 2019.

Financial Statements